Get it on Google Play

Recursion reports positive trial results for experimental FAP treatment

December 8, 2025 7:30 AM EST Send to a Friend
Recursion Pharmaceuticals (NASDAQ: RXRX) announced results from its Phase 1b/2 TUPELO trial of REC-4881, an experimental treatment for familial adenomatous ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login